Why Study Design Determines What You Can Conclude
A 10-year cohort study (n = 20,000) found:
Light wine drinkers had 30% lower MI risk vs non-drinkers.
Headlines: “Wine is Cardioprotective!”
But wait — wine drinkers also:
The wine–MI association may be entirely due to confounding by socioeconomic status and lifestyle.
This module teaches you to think critically about how a study was designed before trusting what it found.
Clue: This design takes a snapshot — everything is measured at one time point.
Answer: Cross-sectional study — population → classify exposed/non-exposed → assess outcome simultaneously.
Purpose: Snapshot — measure exposure and outcome at the same time
How it works:
Key features:
Measure: Prevalence, Prevalence Odds Ratio (POR)
Example: Measuring BP and salt intake in 500 adults at a health camp
| Disease + | Disease − | |
|---|---|---|
| Exposed | a | b |
| Non-exposed | c | d |
Prevalence = (a + c) / (a + b + c + d) — proportion with disease at that time point
Prevalence Odds Ratio = (a × d) / (b × c) — how much more common is disease among exposed?
Limitation: You measured exposure and outcome simultaneously — you can’t tell which came first. Association ≠ temporal sequence.
Clue: This design starts from the outcome and looks backward in time. Efficient for rare diseases.
Answer: Case-control study — select cases & controls → ascertain past exposure.
Purpose: Start with the disease and look backward for exposure
How it works:
Key features:
Measure: Odds Ratio (OR = ad/bc)
Example: 100 oral cancer patients + 200 controls — asked about paan chewing history
| Cases | Controls | |
|---|---|---|
| Exposed | a | b |
| Non-exposed | c | d |
Odds Ratio = (a × d) / (b × c)
Why not RR? You selected cases and controls separately — you don’t know the total population at risk, so you can’t calculate incidence.
Clue: Everyone starts disease-free. You classify by exposure and follow forward over time.
Answer: Cohort study — disease-free population → classify exposed/non-exposed → follow up for outcome.
Purpose: Start with exposure and follow forward to see who develops disease
How it works:
Key features:
Measure: Relative Risk (RR), Absolute Risk, Incidence
Example: Follow 5,000 factory workers (smokers vs non-smokers) for 10 years for lung disease
| Disease + | Disease − | Total | |
|---|---|---|---|
| Exposed | a | b | a + b |
| Non-exposed | c | d | c + d |
Risk in exposed = a / (a + b) Risk in non-exposed = c / (c + d)
Relative Risk (RR) = Risk in exposed / Risk in non-exposed
Absolute Risk Difference = Risk in exposed − Risk in non-exposed
Why cohort can do this but case-control can’t: You followed a defined population forward — so the denominators (a+b, c+d) represent the actual groups at risk.
Clue: Looks like a cohort — but the allocation to groups is done by the investigator, not nature. The red arrows are the giveaway.
Answer: Randomized Controlled Trial — eligible participants → randomize to treatment/control → follow up for outcome.
Purpose: The gold standard — test whether an intervention causes the outcome
How it works:
Key features:
Measure: RR, ARR, NNT
Example: Randomly assign 200 diabetics to yoga vs standard care for 6 months
| Event | No Event | Total | |
|---|---|---|---|
| Treatment | a | b | a + b |
| Control | c | d | c + d |
Control Event Rate (CER) = c / (c + d) Treatment Event Rate (TER) = a / (a + b)
Absolute Risk Reduction (ARR) = CER − TER
Number Needed to Treat (NNT) = 1 / ARR — how many patients must be treated to prevent one event
Clinical meaning of NNT: If NNT = 20, you treat 20 patients to prevent 1 bad outcome. Lower NNT = more clinically impactful treatment.
| Feature | Cross-sectional | Case-control | Cohort | RCT |
|---|---|---|---|---|
| Starting point | Population | Outcome | Exposure | Random assignment |
| Time direction | Snapshot | Backward | Forward | Forward |
| Measure | Prevalence, POR | OR | RR, AR | RR, ARR, NNT |
| Can show causation? | No | Suggests | Suggests | **Yes** |
| Best for rare... | Neither | **Disease** | **Exposure** | N/A |
| Time & cost | Low | Low | High | Very high |
| Main threat | Temporal ambiguity | Recall bias | Loss to follow-up | Ethical constraints |
Key identifier: What is the starting point? Disease → case-control. Exposure → cohort. Random allocation → RCT.
| Research Question | Best Design | Why |
|---|---|---|
| What is the prevalence of diabetes in rural MP? | Cross-sectional | Snapshot of a population |
| Is gutka associated with oral cancer? | Case-control | Oral cancer is rare; start from cases |
| Does air pollution increase asthma in children? | Cohort | Follow exposed vs non-exposed over time |
| Does a new drug lower BP more than standard? | RCT | Need causal evidence for treatment |
| Is a screening test effective at reducing mortality? | RCT (or large cohort) | Lead-time bias threatens observational designs |
The choice depends on: research question, outcome frequency, time, ethics, and resources.
Systematic error in how participants are selected or retained.
Common types:
Example:
Study of phone radiation and brain cancer using hospital controls.
Key principle: Selection bias cannot be corrected after data collection. It must be prevented by design.
Systematic error in how exposure or outcome is measured.
| Type | What Happens | Example |
|---|---|---|
| Recall bias | Cases remember exposure better than controls | Mothers of malformed babies recall drug use more |
| Observer bias | Assessor knows exposure status | Unblinded radiologist reads scans differently |
| Misclassification | Wrong category assignment | BP cuff too small → systematic overestimation |
| Hawthorne effect | Behavior changes when observed | Hand hygiene improves during audit |
Solutions: Blinding, standardized instruments, objective measures, validated questionnaires
A confounder is a variable that:
Example: SES confounds the wine → heart disease association (see clinical hook)
After adjusting for SES and lifestyle, the wine–CVD association largely disappears.
| Stage | Method | How It Works |
|---|---|---|
| Design | Randomization | Distributes ALL confounders equally (known + unknown) |
| Design | Restriction | Limit to one stratum (e.g., only males) |
| Design | Matching | Select controls with same confounder values |
| Analysis | Stratification | Analyze within confounder strata separately |
| Analysis | Multivariable regression | Adjust for confounders in model |
Only randomization controls for UNKNOWN confounders. All other methods require you to identify and measure confounders in advance.
Higher = stronger evidence for causation — but not always feasible or ethical!
A district hospital in Madhya Pradesh screens 800 pregnant women attending their first antenatal visit. Blood samples are drawn for haemoglobin, and a questionnaire records dietary iron intake. The researchers want to estimate anaemia prevalence and its association with diet.
Cross-sectional — Exposure (diet) and outcome (anaemia) measured at the same time point. No follow-up, no selection by disease. The giveaway: “screens at first visit” = single snapshot.
Researchers at a cancer centre identify 150 patients with gallbladder carcinoma and select 300 age- and sex-matched patients admitted for unrelated surgeries. Both groups are interviewed about typhoid history, use of mustard oil, and family history.
Case-control — Started from the disease (gallbladder cancer), selected controls, and looked backward at past exposures. The giveaway: “identify patients with disease” + “interviewed about past history.”
A research team enrols 3,000 non-diabetic adults aged 30–50 from an urban slum in Pune. At baseline, they record physical activity levels, BMI, and fasting glucose. They follow the cohort for 8 years, checking annually for new-onset type 2 diabetes.
Cohort — Everyone was disease-free at start, classified by exposure (physical activity), and followed forward for outcome. The giveaway: “non-diabetic at enrolment” + “follow for 8 years.”
Forty primary health centres in Chhattisgarh are randomly allocated: 20 receive a mHealth reminder system for DOTS adherence, 20 continue with usual care. After 12 months, TB treatment completion rates are compared.
Cluster RCT — The investigator randomly allocated the intervention. Groups were followed forward and outcomes compared. The giveaway: “randomly allocated” — nature didn’t decide, the researcher did. (Cluster because the unit of randomization is the PHC, not individual patients.)
| Country | Crude Death Rate | Life Expectancy |
|---|---|---|
| India | 6.4 | 70.8 years |
| Sweden | 9.0 | 83.2 years |
Sweden’s crude death rate is 41% higher — yet Swedes live 12 years longer!
. . .
Why? Sweden has 29% of its population aged 60+, vs 18% in India. More elderly = more deaths = higher crude rate.
Age is confounding the comparison.
Question: What would each country’s death rate be if both had the same age structure?
Method: Apply each country’s age-specific rates to a common standard population.
| Age Group | Standard Weight (Wᵢ) | India ASDR (Rᵢ) | Wᵢ × Rᵢ | Sweden ASDR (Rᵢ) | Wᵢ × Rᵢ |
|---|---|---|---|---|---|
| 0–14 | 0.264 | 2.8 | 0.739 | 0.3 | 0.079 |
| 15–44 | 0.378 | 1.5 | 0.567 | 0.4 | 0.151 |
| 45–59 | 0.172 | 5.2 | 0.894 | 2.8 | 0.482 |
| 60–74 | 0.118 | 22.0 | 2.596 | 12.0 | 1.416 |
| 75+ | 0.068 | 80.0 | 5.440 | 72.0 | 4.896 |
| Total (ASR) | 10.24 | 7.02 |
After standardization: India (10.2) > Sweden (7.0) — the truth emerges!
\[\text{Age-Standardized Rate} = \sum_{i} W_i \times R_i\]
| Kerala | Bihar | |
|---|---|---|
| % Population 60+ | 26% | 13% |
| Crude Death Rate | 7.4 | 5.8 |
| Age-Standardized Rate | 5.6 | 8.1 |
| Life Expectancy | 76.3 yrs | 69.2 yrs |
Kerala’s crude rate appears higher — but after standardization, Bihar’s rate is 45% higher.
Kerala is healthier at every age. It just has more elderly people (demographic transition).
When to use: Small populations where age-specific rates are unstable (few deaths per group).
Method: Apply the standard population’s rates to your population’s age structure → get expected deaths.
\[\text{SMR} = \frac{\text{Observed deaths}}{\text{Expected deaths}} \times 100\]
Example: A thermal power plant town in Chhattisgarh
| Observed | Expected (based on India rates) | |
|---|---|---|
| Total deaths | 103 | 75 |
| SMR | 137 |
Interpretation: 37% excess mortality compared to national average, after accounting for age structure.
Critical rule: SMRs from different populations are NOT comparable to each other. Only compare each SMR to 100 (the reference).
| Direct | Indirect | |
|---|---|---|
| Apply | Study rates → standard weights | Standard rates → study weights |
| Need | Reliable age-specific rates | Only age structure + total deaths |
| Get | Age-standardized rate | SMR (ratio) |
| Compare? | Yes — rates are directly comparable | No — SMR only vs reference (100) |
| Best for | Large populations | Small populations |
Remember: Standardized rates are fictional — they tell you what would happen under a hypothetical age structure. Use crude rates for healthcare planning; use standardized rates for fair comparisons.
Biostatistics for Clinicians | Module 7